Bristol Myers Squibb
DC · 15 filings, 2025
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States. via Wikipedia ↗
1Lobbies on
Its filings list: Medicare/Medicaid · Health Issues · Budget/Appropriations · Trade (domestic/foreign) · Taxation/Internal Revenue Code · Copyright/Patent/Trademark
2Through these firms · 5
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5236A bill to amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services…
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5227A bill to amend the Internal Revenue Code of 1986 to allow certain distributions from long-term qualified t…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5224A bill to improve training for airport drivers in the movement area at commercial service airports through…